



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)		
(51) International Patent Classification 6:		(11) Internati nal Publication Number: WO 97/04133
C12Q 1/68, C07K 14/705, 16/28, G01N 33/566	A1	(43) International Publication Date: 6 February 1997 (06.02.97)
(21) International Application Number: PCT/US	596/1200	(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility
(22) International Filing Date: 19 July 1996 ((19.07.9	
(30) Priority Data: 60/001,387 21 July 1995 (21.07.95) 60/001,861 3 August 1995 (03.08.95) 60/016,700 2 May 1996 (02.05.96) (71) Applicant (for all designated States except US): REGITHE UNIVERSITY OF MINNESOTA [USUS]]; Morr	LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Hall, 100 Church Street, S.E., Minneapolis, MN 55 (72) Inventors; and (75) Inventors/Applicants (for US only): TSILIBARY, Effie [US/US]; 1812 Emerson Avenue South, Min MN 55403 (US). CHARONIS, Aristidis, S. [US/U Emerson Avenue South, Minneapolis, MN 554 SETTY, Suman [IN/US]; Apartment 1703, 425 15t S.E., Minneapolis, MN 55414 (US). MAUER, [US/US]; 2507 West 52nd Street, Minneapolis, M (US).	Photin nneapoli US]; 181 W03 (US th Avenu Micha	Published i- S, Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. i- Color of the claims and to be republished in the event of the receipt of amendments.
(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smi Welter & Schmidt, 3100 Norwest Center, 90 South		

(54) Title: ANALYSIS OF ALPHA INTEGRINS FOR THE DIAGNOSIS OF DIABETIC NEPHROPATHY

(57) Abstract

Street, Minneapolis, MN 55402 (US).

Analysis of alterations in integrin subunit expression, particularly $\alpha 1$ and/or $\alpha 2$ integrin subunit expression from integrin producing cells as compared to normal controls as a diagnostic method to identify individuals who have or are predisposed to pathologies associated with altered matrix deposition, such as diabetic renal nephropathy.